ARIDIS PHARMACEUTICALS INC (ARDS) Stock Fundamental Analysis

NASDAQ:ARDS • US0403341045

0.3101 USD
+0.05 (+17.91%)
At close: Jul 18, 2023
0.2619 USD
-0.05 (-15.54%)
After Hours: 7/18/2023, 8:14:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

ARDS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. ARDS may be in some trouble as it scores bad on both profitability and health. ARDS is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ARDS has reported negative net income.
  • In the past year ARDS has reported a negative cash flow from operations.
ARDS Yearly Net Income VS EBIT VS OCF VS FCFARDS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • ARDS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARDS Yearly ROA, ROE, ROICARDS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 -600 -800

1.3 Margins

  • ARDS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARDS Yearly Profit, Operating, Gross MarginsARDS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • ARDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ARDS has more shares outstanding
  • Compared to 1 year ago, ARDS has an improved debt to assets ratio.
ARDS Yearly Shares OutstandingARDS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
ARDS Yearly Total Debt VS Total AssetsARDS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

  • ARDS has an Altman-Z score of -43.31. This is a bad value and indicates that ARDS is not financially healthy and even has some risk of bankruptcy.
  • ARDS has a Altman-Z score of -43.31. This is amonst the worse of the industry: ARDS underperforms 96.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -43.31
ROIC/WACCN/A
WACC8.46%
ARDS Yearly LT Debt VS Equity VS FCFARDS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.19 indicates that ARDS may have some problems paying its short term obligations.
  • The Current ratio of ARDS (0.19) is worse than 99.15% of its industry peers.
  • ARDS has a Quick Ratio of 0.19. This is a bad value and indicates that ARDS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ARDS has a worse Quick ratio (0.19) than 99.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ARDS Yearly Current Assets VS Current LiabilitesARDS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.11% over the past year.
  • Looking at the last year, ARDS shows a quite strong growth in Revenue. The Revenue has grown by 9.70% in the last year.
  • The Revenue has been growing by 29.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)53.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
Revenue 1Y (TTM)9.7%
Revenue growth 3Y44.71%
Revenue growth 5Y29.16%
Sales Q2Q%-8.85%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.36% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 145.96% on average over the next years. This is a very strong growth
EPS Next Y71.9%
EPS Next 2Y46.13%
EPS Next 3Y40.36%
EPS Next 5YN/A
Revenue Next Year1609.12%
Revenue Next 2Y334.44%
Revenue Next 3Y225.86%
Revenue Next 5Y145.96%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARDS Yearly Revenue VS EstimatesARDS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
ARDS Yearly EPS VS EstimatesARDS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARDS. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 1.17 indicates a rather cheap valuation of ARDS.
  • 99.66% of the companies in the same industry are more expensive than ARDS, based on the Price/Forward Earnings ratio.
  • ARDS is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.17
ARDS Price Earnings VS Forward Price EarningsARDS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDS Per share dataARDS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • ARDS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ARDS's earnings are expected to grow with 40.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.13%
EPS Next 3Y40.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ARDS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ARIDIS PHARMACEUTICALS INC

NASDAQ:ARDS (7/18/2023, 8:14:23 PM)

After market: 0.2619 -0.05 (-15.54%)

0.3101

+0.05 (+17.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-08
Earnings (Next)08-14
Inst Owners0%
Inst Owner Change0%
Ins Owners20.6%
Ins Owner Change0%
Market Cap11.23M
Revenue(TTM)2.99M
Net Income(TTM)-29.42M
Analysts80
Price Target10.2 (3189.26%)
Short Float %0.1%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.47%
Min EPS beat(2)-43.47%
Max EPS beat(2)-43.47%
EPS beat(4)0
Avg EPS beat(4)-283.27%
Min EPS beat(4)-635.29%
Max EPS beat(4)-43.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)285.7%
Min Revenue beat(2)285.7%
Max Revenue beat(2)285.7%
Revenue beat(4)1
Avg Revenue beat(4)31.22%
Min Revenue beat(4)-97.26%
Max Revenue beat(4)285.7%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)66.67%
PT rev (3m)66.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)33.33%
EPS NY rev (3m)33.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)47.06%
Revenue NY rev (3m)47.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.17
P/S 3.76
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)0.27
Fwd EY85.52%
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.08
BVpS-0.77
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.77%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -43.31
F-Score4
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)82.04%
Cap/Depr(5y)107.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
EPS Next Y71.9%
EPS Next 2Y46.13%
EPS Next 3Y40.36%
EPS Next 5YN/A
Revenue 1Y (TTM)9.7%
Revenue growth 3Y44.71%
Revenue growth 5Y29.16%
Sales Q2Q%-8.85%
Revenue Next Year1609.12%
Revenue Next 2Y334.44%
Revenue Next 3Y225.86%
Revenue Next 5Y145.96%
EBIT growth 1Y33.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.29%
OCF growth 3YN/A
OCF growth 5YN/A

ARIDIS PHARMACEUTICALS INC / ARDS FAQ

What is the ChartMill fundamental rating of ARIDIS PHARMACEUTICALS INC (ARDS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ARDS.


What is the valuation status for ARDS stock?

ChartMill assigns a valuation rating of 4 / 10 to ARIDIS PHARMACEUTICALS INC (ARDS). This can be considered as Fairly Valued.


How profitable is ARIDIS PHARMACEUTICALS INC (ARDS) stock?

ARIDIS PHARMACEUTICALS INC (ARDS) has a profitability rating of 0 / 10.